Bipartisan EPIC Act a "critical step forward" to incentivize small molecule drug innovation

Yesterday, Reps. Greg Murphy, M.D. (R-NC), Don Davis (D-NC) and Brett Guthrie introduced the Ensuring Pathways to Innovative Cures (EPIC Act), legislation to fix the “pill penalty.” BIO President and CEO, Rachel King, made the following statement:

“The bipartisan introduction of the Ensuring Pathways to Innovative Cures (EPIC) Act is a critical step toward removing a punitive penalty on the development of small-molecule medicines, a vital class of treatments for patients around the globe. This legislation would fix a section of the Inflation Reduction Act and make certain that we are not disincentivizing the development of small molecule drugs that are often more accessible for patients. 

“We need to ensure that public policy is keeping pace with the groundbreaking medical advances happening in labs across the country. We owe it to patients to make certain that these medical advances are not stifled by short-sighted public policy.  BIO strongly supports this important legislation, and we commend Representatives Murphy, Davis and Guthrie for their tireless work on behalf of patients and their continued efforts to make the U.S. a leader in medical innovation.”